Assessment of Efficacy, Tolerability and Safety of Steroneo Skin Cream (Physalis Angulata Supercritical Extract) application for treatment of eczematous lesions: A Prospective, Open-label, Non-Comparative Study

Rehmat Clinic0 个研究点目标入组 50 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•Clinically diagnosed with eczematous lesions of any of the following types and requiring mild to moderate topical steroid therapy:
•Atopic dermatitis
•Contact dermatitis
•Xerotic eczema
•Nodular eczema
•Seborrheic dermatitis
•Neurocutaneous dermatitis (lichen simplex chronicus)
•Drug eruptions, photo-dermatitis
•Pruritus requiring topical corticosteroids
•Patients/parents who sign the written informed consent form
•Patients willing to and able to understand and comply with all study requirements

•1.Patients having any of the following conditions:
•Lichen planus
•Severe dermatitis requiring systemic corticosteroids
•Infantile dermatitis
•2.Patients requiring systemic corticosteroids on any form
•3.Pregnant and lactating women
•4.Patients with known hypersensitivity to any of the ingredients/excipients of the study cream
•5.Any other condition, which in the opinion of the clinician/investigator, could interfere significantly with the treatment and assessment process
•6.Use of any investigational therapy within 30 days prior to randomization
•7.Patients not willing to provide written informed consent

发起方

Rehmat Clinic